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A randomized phase 11 trial of interleukin 2 and
interleukin 2-interferon alpha in advanced renal cancer
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CRC Department of Medical Oncology. Chnstie Hospital. Wthington. Manchester M20 4BX. UK
Summary A randomized phase 11 trial was performed to compare the efficacy and toxicity of interleukin 2 (IL-2) with an IL-2 and interferon
alpha (IFN-a) regimen for the treatment of metastatic renal carcinoma. Sixty patients with recurrent renal cell carcinoma (RCC) who had
previously undergone a nephrectomy were randomized to receive three cycles of IL-2 or IL-2 with IFN-a,. Eighteen MU of IL-2 were
administered subcutaneously on Mondays-Fridays for 3 weeks out of 4. Those patients randomized to receive the combination received the
same regimen of IL-2 with 9 MU of IFN-ac2 subcutaneously on Mondays, Wednesdays and Fridays for 3 weeks out of 4. Thirty patients were
randomized to receive each arm. Twenty-nine were evaluable in each arm. Twenty-two patients received three cycles of IL-2 but only 14
patients received three cycles of IL-2I1FN-a because of the greater toxicity of the combination. The principal toxicities included nausea,
fatigue and fever. There were no complete responses in either arm and only two patients who were treated with IL-2 attained a partial
response. Twelve patients in each arm had stable disease and 15 patients in the IL-2 arm and 16 patients in the IL-2/IFN-a arm progressed
through treatment. There were no significant differences in survival. Ten patients who received IL-2 are alive with a median follow-up of 266
days, whereas six patients who received IL-2/IFN-a are alive after a median of 278 days. The median survival from the time of identification
of metastatic disease is 444 days in the IL-2 arm and 381 days in the IL-2/IFN-a arm. The IL-2I1FN-a combination is more toxic than IL-2
alone and this resulted in a reduced number ofcycles of treatment. However, the median survival of the two groups was the same, suggesting
that further evaluation of the IL-2/IFN-a combination should be confined to large prospective randomized clinical trials.
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The treatment of metastatic renal carcinoma (RCC) is frustrating,.
Chemotherapy is largely ineffecti-e and standard therapy revolves
around the administration ofcvtokines such as interleukin 2 (LL-2)
and interferon alpha (dFN-c). Typically. these agents are associ-
ated with an objectixe response rate of 15-207c. although higher
doses of IL-2 have been reported to induce a 30%7c response rate
(Canobbio et al. 1996a: Goev et al. 1996: Savage et al. 1996).
Response rates and sun-ix-al are strongly influenced by patient
selection so that those who have a good performance status. a
single site of metastatic disease and a prolonged disease-free
interxal follow-ing initial surgery fare better (Palmer et al. 1992:
Fossa et al. 1995: Canobbio et al. 1996a: Goey et al. 1996: Savage
et al. 1996).
Experimental data suggested that a combination of IL-2 and
IFN-a might offer superior efficacy. Interferon enhances the cell
membrane expression of major histocompatibility complex
(MHC) antigens to %%-hich IL-2-activated T cells can respond
(Guadagni et al. 1989). A sxnergistic response was confirmed in
mice (Cameron et al. 1988) and this led to the development of
combination regimens that were associated wvith an oxerall
response rate of up to 29%7 (Atzpodien et al. 1990. 1991. 1995:
Palmer et al. 1993: Canobbio et al. 1996b: Gause et al. 1996:
Savage et al. 1996) wxith a median survival of 8-12 months
(Facendola et al. 1995: Canobbio et al. 1996a). Nexertheless. the
toxicity of combination cytokine therapy includes fatiglue.
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hN-potension and creatinine elexvation (Atkins et al. 1993: Gause et
al. 1996). factors that led to the premature discontinuation of
therapy in 14% ofpatients (Facendola et al. 1995).
We haxe performed a phase I trial to determine the maximum
tolerated dose of an IL-2/WFN-a combination that xxould allou- the
administration of 3 months of treatment. This studv showed that
the maximum tolerated dose involxed the subcutaneous adminis-
tration of IL-2 18 MU from Mondav to Fridav with IFN-a 9 MU
Mondav. Wednesdav and Fridax for 3 of exerv 4 %veeks (unpub-
lished). We now report the results of a prospectixe randomized
phase II trial that compares the efficacy and toxicitx of IL-2 with
IL-2 and IFN-a.
PATIENTS AND METHODS
Patients
Sixtv patients wxith progressixve metastatic RCC were randomized.
between 1993 and 1996. to receive IL-2 or IL-2IIFN-a,. All had
undergone a nephrectomy for RCC and had radiological evidence
of recurrent and/or metastatic RCC. None of the patients had
undergone prior therapy for the disease. The following eligibility
criteria for the trial applied: prexious nephrectomv for RCC:
evidence of recurrent or metastatic disease that was evaluable:
Karnofsky performance status > 70: adequate organ function
(serum creatinine < 150 lmI. lixer transaminases < twice the upper
limit of normal. bilirubin < 20 m.t white cell count > 3 x 109 1-1.
platelet count > 100 x 109 1-1). Patients wxith brain metastasis.
severe central nervous system disease or sexvere cardiac disease
were excluded from the trial. The protocol wxas approxved by the
South Manchester Ethical Rexiexx Committee.
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Treatment regimen
Thirty patients were randomized to receive IL-2 alone. This
involved the subcutaneous administration of 18 MU of IL-2
(Chiron) from Mondav to Fridav for 3 ofevery 4 weeks. An addi-
tional week off treatment was permitted if side-effects had failed
to settle at the time of out-patient review in the fourth week. This
defined one cycle of treatment and patients were given three
cycles oftherapy.
Thirt- patients were randomized to receive 1L-2 wAith IFN-cat,
(Roche). The IL-2 was administered as above. IFN-ax, (9 MU)
was aiven on Mondays. Wednesdays and Fridavs for 3 of everv
4 weeks. An additional week off treatment was granted if side-
effects were too severe. In the event ofgrade III fever or rigors the
dose of IFN was reduced to 6 MU.
The first doses of IL-2 or IL-2/WFN-ct, were administered in
hospital with 400 mc of ibuprofen and 500 mg of paracetamol
premedication. If the treatment A-as well tolerated the rest of the
cvtokine therapy A-as given in the outpatient setting. The use of
steroids was not permitted during, the trial.
Evaluation of efficacy
Patients underw ent a full ex aluation of their disease by
computer tomographic assessment of chest and abdomen before
and after treatment. Serial chest radiographs were performed
after each cycle of therapy and blood samples were taken for
biochemical and haematological evaluation before each cycle
of therapy. WHO response criteria were used for the analysis
(WHO. 1979). A complete response was defined as the
complete disappearance of all clinical and laboratory evidence
ofdisease for at least a month. A partial response was defined as
> 50% reduction in the sum of the products of the diameters of
all of the measurable lesions for at least 4 weeks. Progressive
disease was defined as an increase of > 25%7 in the products of
the perpendicular diameters of any lesion. Stable disease w as
defined as that which was neither a response nor progressive
disease. The trial had an 80% chance of detecting a 30%
improvement in surx ival.
Evaluation of toxicity
Toxicity was evaluated according to National Cancer Institute
common toxicity criteria (NCI-CTC).
RESULTS
Patient characteristics
Table 1 shows the patient characteristics. The patients w-ere
eligible ifthey had undergone anephrectomy and had radiological
evidence of recurrent or metastatic disease with a Kamofsk-v
performance status > 70. Seventeen patients who were treated with
IL-2 and 18 who received LL-2/IFN-t,b had two or more sites of
metastatic disease. The interval from initial therapy to the time of
diagnosis of metastatic disease was 237 days in the IL-2 arm and
292 days in the IL-2/IFN-a,b arm.
One patient on each arm w-as excluded from the analysis
because of inadequate histological verification. A further patient
Awas excluded from the IL-2/IFN-crx arm because ofangyina.
Table 1 Patient charactenstics
IL-2 IL-2JIFN-a2b
n 30 30
Median age (range) 53 years (34-71) 56 years (30-71)
Sex M:F 19:11 18:12
Stage at diagnosis
1 or2 5 9
3 or 4 16 15
Not known 9 6
No previous radiotherapy 26 24
Sites of metastasis
Lung 22 24
Soft tissue 11 10
Abdominal nodes 8 10
Liver 7 3
Bone 5 4
Subcutaneous 4 2
Penrenal nodes 2 0
Mediastinum 7 2
Response and survival
No complete responses and only two partial responses occurred in
the IL-2 ann. Twelve patients in each group attained a stabilization
of disease. whereas 15 (5 1%) in the 11-2 and 16 (571%) in the IL-
2[IFN-a, arms progressed through therapy. The median survival
of patients from the time of diagnosis of recurrent or metastatic
disease was 4-4 days in the IL-2-treated patients and 381 days in
the WL-2/IFN-Cx,b arm (Figure 1). In addition. there was a trend to
suggest that those patients who were treated with IL-2 alone had a
longer time to progression after therapy. although this was not
statistically sianificant (Figure 2).
Toxicity of treatment
The toxicity of the cytokines resulted in 26 and 22 patients
receiving two and three cycles of IL-2 therapy. whereas only 25
and 14 patients received 2 and 3 cycles of IL-2IFN-ax, treatment
respectively. The principal toxicities ofthe therapy are recorded in
Table 2. which shows that the IL-2AIFN-cx,2 combination was asso-
ciated with more fatigue and vomiting than IL-2 alone. Grade 4
vomiting was seen in one patient who was treated with the IL-
2IIFN-tx, combination. leading to premature discontinuation of
the treatment. One patient who was treated with IL-2AIFN-a.
dexveloped grade III pyrexia during the second cycle and discon-
tinued therapy. and two others stopped after the dexelopment of
arade III somnolence in cycles 1 and 2 respectively. Two patients
who were treated with IL-2 and one who was treated with
IL-2/IFN-a.t, developed transient and asymptomatic grade 4
lymphopenia. Fluid retention and oedema were not prominent
toxicities. The injection sites associated with IL-2 administration
were the most painful and frequently produced tender nodules.
However. there were no differences in the prevalence of this
complication between the two groups. Although the side-effects of
the 1L-2 regrimen abated during each cycle. those associated with
the IL-2AIFN-otb did not. leading to more prolonged episodes of a
particular grade oftoxicity.
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Figure 1 Survival from time of diagnosis of metastatic disease. Interleukin
2, solid line, IL-2AFN-a, dotted line (P= 0.98)
DISCUSSION
The treatment of metastatic renal cancer revolves around the
administration of agents such as IL-2 and IFN-a. These drugs are
associated with a 20% response rate and a median survival of
approximately 8 months after the diagnosis of metastatic disease
(Canobbio et al. 1996a: Goey et al. 1996: Savage et al, 1996). This
randomized phase II trial was performed to derive further informa-
tion about the toxicity and efficacy of combination cytokine
therapy. The data show that the combination of IL-2 and IFN-a2
was more toxic than IL-2 alone, resulting in the administration of
significantly fewer cycles of treatment to the former group.
The response rates in this study were disappointing. In part this
may have been due to the high percentage ofpatients who had two
or more sites of metastatic disease. an established prognostic
factor (Palmer et al. 1992: Canobbio et al. 1996b: Fossa et al.
1995: Goey et al. 1996: Savage et al. 1996). In series that have
investigated patients with two or more sites of disease, the
response rates can be as low as 8% (Canobbio et al. 1995). On the
other hand. the objective response rate is higher in studies in
which most patients have one site of metastatic disease
(Atzpodien et al. 1995: Tourani et al. 1996).
The median survival intervals of the patients in the two arms
were similar and compare favourably with the results of other
assessments of IL-2 (Walpole et al. 1993: Tourani et al, 1996).
Those who were treated with IL-2 alone survived for a median of
14.6 months, whereas those who received the IL-2A/FN-ao,b combi-
nation survived for a median of 12.5 months, statistics that match
those of other investigations of IL-2AFN-a2b combinations
Figure 2 lime to progression after cytoline therapy. IL-2. solid line;
IL-21FN-,, dotted line (P= 0.18)
Table 2 Principal toxicities of IL-2 and IL-2/1FN. The percentage of cycles
associated with grade 2 or 3 toxicity
IL-2 IL-2/IFN-ab
Fatigue 56 69
Nausea/vomitng 36 47
Fever 40 39
Dyspnoea 8 12
Diarrhoea 9 9
(Facendola et al, 1995). Recent studies have developed a number
of prognostic factors for patients treated with a continuous infu-
sion of IL-2 (Palmer et al. 1992). The performance status. the
interval from diagnosis to treatment and the number of metastatic
sites were considered important factors and were validated on
independent cohorts of patients. Those with all three factors
survived for a median of5 months, whereas those with two factors
survived for a median of 9 months. Those with one risk factor
survived for a median of 18 months and those with none survived
for 28 months. In our population 60% had disease in more than one
site and the median progression-free interval after initial surgery
was approximately 8-9 months. These factors would predict a
median survival of 9 months. Yet the patients in this report
survived for a median of 12-14 months, comparing favourably
with other author's reports. This suggests that IL-2-based treat-
ment has extended the lifespan of ourpatients. despite a low objec-
tive response rate.
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The increased toxicity of this cytokine combination suggests
either that further evaluation of the IL-2/IFN-aL, combination
should be confined to large prospective randomized trials or that
the less toxic but more active 5-fluorouracil /IL-2/IFN-a,, combi-
nations (Atzpodien et al, 1993) should be fiunher explored.
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